• Explore /
  • Poster
  • / Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.

Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Toni K. Choueiri , Piotr Tomczak , Se Hoon Park , Balaji Venugopal , Tom Ferguson , Stefan N. Symeonides , Jaroslav Hajek , Yen-Hwa Chang , Jae-Lyun Lee , Naveed Sarwar , Antoine Thiery-Vuillemin , Marine Gross-Goupil , Mauricio Mahave , Naomi B. Haas , Piotr Sawrycki , Howard Gurney , Lei Xu , Kentaro Imai , Jackie Rogerio , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03142334

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4512)

DOI

10.1200/JCO.2022.40.16_suppl.4512

Abstract #

4512

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Toni K. Choueiri

First Author: Tae Gyun Kwon

First Author: Makoto Nishio